{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:41Z","timestamp":1789011581506,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,7,29]],"date-time":"2013-07-29T00:00:00Z","timestamp":1375056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2013,10]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Currently, acyclovir (ACV<\/jats:styled-content>) at 1000\u00a0mg\/day is widely used as prophylaxis in the early phase of hematopoietic stem cell transplant (HSCT<\/jats:styled-content>) in Japan. However, low\u2010dose ACV<\/jats:styled-content> (200\u00a0mg\/day) has been shown to prevent varicella zoster virus reactivation in the middle and late phases of HSCT<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>Therefore, in this study, we decreased the dose of ACV<\/jats:styled-content> to 200\u00a0mg\/day in the early phase after HSCT<\/jats:styled-content>. We analyzed 93 consecutive herpes simplex virus (HSV<\/jats:styled-content>)\u2010seropositive patients who underwent allogeneic HSCT<\/jats:styled-content> for the first time in our center between J<\/jats:styled-content>une 2007 and D<\/jats:styled-content>ecember 2011.<\/jats:p><\/jats:sec>Results<\/jats:title>Before A<\/jats:styled-content>ugust 2009, 38 patients received oral ACV<\/jats:styled-content> at 1000\u00a0mg\/day (ACV<\/jats:styled-content>1000) until day 35 after HSCT<\/jats:styled-content>, whereas 55 patients received oral ACV<\/jats:styled-content> at 200\u00a0mg\/day (ACV<\/jats:styled-content>200) after S<\/jats:styled-content>eptember 2009. We compared the cumulative incidence of HSV<\/jats:styled-content> infection in the 2 groups. Oral ACV<\/jats:styled-content> was changed to intravenous administration because of intolerance in 66% and 45% of the patients in the ACV<\/jats:styled-content>1000 and ACV<\/jats:styled-content>200 groups, respectively (P<\/jats:italic>\u00a0=\u00a00.060). The probability of severe stomatitis (Bearman grade II<\/jats:styled-content>\u2013III<\/jats:styled-content>) was 76% and 60% in the ACV<\/jats:styled-content>1000 and ACV<\/jats:styled-content>200 groups, respectively (P<\/jats:italic>\u00a0=\u00a00.12). The number of patients who developed HSV<\/jats:styled-content> disease before day 100 after HSCT<\/jats:styled-content> was 0 in the ACV<\/jats:styled-content>1000 group and 2 in the ACV<\/jats:styled-content>200 group, with a cumulative incidence of 3.6% (P<\/jats:italic>\u00a0=\u00a00.43). HSV<\/jats:styled-content> disease in the latter 2 patients was limited to the lips and tongue and was successfully treated with ACV<\/jats:styled-content> or valacyclovir at a treatment dose.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>ACV<\/jats:styled-content> at 200\u00a0mg\/day appeared to be effective for preventing HSV<\/jats:styled-content> disease in the early phase after HSCT<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12118","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T04:54:01Z","timestamp":1375160041000},"page":"457-465","source":"Crossref","is-referenced-by-count":37,"title":["Low\u2010dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"15","author":[{"given":"K.","family":"Kawamura","sequence":"first","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wada","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ashizawa","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Machishima","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Terasako","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2010I.","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nakasone","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kako","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tanihara","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nishida","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Hematology Saitama Medical Center Jichi Medical University Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.3.338"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198107093050202"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92248-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6389.384"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-6-823"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/16.3.389"},{"issue":"3","key":"e_1_2_6_8_1","first-page":"145","article-title":"Prevention of herpes simplex virus (HSV) infection in recipients of HLA\u2010matched T\u2010lymphocyte\u2010depleted bone marrow allografts","volume":"24","author":"Engelhard D","year":"1988","journal-title":"Isr J Med Sci"},{"issue":"10","key":"e_1_2_6_9_1","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"49","author":"CDC","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21152"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.130"},{"issue":"6","key":"e_1_2_6_12_1","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka D","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200202270-00015"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.10.1562"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1999.10474144"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198705000-00010"},{"issue":"2","key":"e_1_2_6_19_1","first-page":"185","article-title":"Long\u2010term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro","volume":"1","author":"Ljungman P","year":"1986","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703214"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447010-00009"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/518938"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1086\/315524"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/314052"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1085"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(02)00263-9"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12118","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T08:36:04Z","timestamp":1695976564000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,29]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/tid.12118"],"URL":"https:\/\/doi.org\/10.1111\/tid.12118","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,29]]}}}